Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | SLC5A2 | P31639 | 12/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.46 |
| ▸ | MGAM | O43451 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13107684 | 0.89 | SLC5A2 (0.47) | ACHESLC5A2SLC5A1 | |
| SCHEMBL13122973 | 0.86 | SLC5A2 (0.48) | ACHESLC5A2SLC5A1 | |
| SCHEMBL13107675 | 0.85 | SLC5A2 (0.59) | ACHESLC5A2SLC5A1 | |
| SCHEMBL3410145 | 0.84 | SLC5A2 (0.37) | SLC5A2SLC5A1MGAM | |
| SCHEMBL6464857 | 0.84 | SLC5A2 (0.37) | SLC5A2SLC5A1MGAM | |
| SCHEMBL4420233 | 0.82 | SLC5A2 (0.35) | SLC5A2SLC5A1 | |
| SCHEMBL3410146 | 0.82 | SLC5A2 (0.35) | SLC5A2SLC5A1 | |
| SCHEMBL3410151 | 0.82 | SLC5A2 (0.35) | SLC5A2SLC5A1 | |
| SCHEMBL4420237 | 0.82 | SLC5A2 (0.35) | SLC5A2SLC5A1 | |
| SCHEMBL1040007 | 0.77 | SLC5A2 (0.59) | ACHESLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816330-B2 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100004188-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | URBANSKI MAUD | 2010-01-07 | — | — | US | disclosed |
| US-20090105165-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | URBANSKI MAUD | 2009-04-23 | — | — | US | disclosed |
| US-7511020-B2 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105165-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | GANAB, GCG, B3GAT3 | ACHE 2238/4885SLC5A2 16/4885SLC5A1 18/4885 |
| US-20100004188-A1 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | GANAB, GCG, GANC | ACHE 2050/4885SLC5A2 18/4885SLC5A1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.